Advanced donor age has been identified as a risk factor when combined with donor warm ischemia time (WIT), eg, in donation after circulatory death (DCD). In several countries, DCD livers older than 60 years are not considered suitable due to concerns related to poor graft function and development of ischemic cholangiopathy. In this study, we evaluate outcomes after DCD liver transplantation using grafts from donors older than 60 years. We analyzed outcomes after DCD liver transplantation (n 5 315), comparing donors > 60 years (n 5 93) and donors £ 60 years (n 5 222) from our center between 2005 and 2015. End points included graft function and complications and patient and graft survival. Multivariate risk analysis was performed to define further key factors that predicted inferior outcome. Donor age at the cutoff 60 years failed to stratify patient and graft survival. The rate of vascular, biliary, and overall complications was comparably low in both cohorts, and the median comprehensive complication index was 42.7 points, independent from the donor age. Second, donor body mass index (BMI) above a threshold of 25 kg/m 2 significantly impacted on graft and patient survival at any donor age, whereas donor WIT and cold ischemia times were not predictive for graft loss. In conclusion, older DCD donors can be successfully used for liver transplantation with good longterm outcomes when further risk factors are limited. Additional risk is transmitted by an increased donor BMI regardless of donor age.
and it uses approximately 80% of the DCD grafts that are offered. (3) Recently, we have demonstrated that with appropriate recipient selection and limitations of donor risk factors, DCD livers yield outcomes similar to donation after brain death transplantation. (3) Nevertheless, during the last 5 years a significant shift of median donor age toward 70 years was noted in our DCD cohort. In this context, we evaluate with this study the outcome after DCD liver transplantation comparing older and younger donors from our center, and we identify further risk factors.
Patients and Methods

DATA COLLECTION AND ANALYSIS
We analyzed DCD liver transplantations at our center (UHB) within 10 years (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . We opted for a donor age of 60 years for the cutoff because several reports have identified this threshold as an independent risk factor for outcome. (1, 2, 9) In both groups (60 versus > 60 years), we analyzed outcome parameters, eg, transfusions, posttransplant liver and kidney injury, intensive care unit (ICU) and hospital stay, overall recipient morbidity (including biliary complications), and mortality.
IC was defined radiologically, as intrahepatic or hilar biliary strictures and dilatations, occurring in the absence of hepatic artery stenosis or hepatic artery thrombosis (HAT), portal thrombosis, chronic ductopenic rejection, and recurrent primary sclerosing cholangitis (PSC). (10) Electronic files for all patients were available at our center and were carefully screened for every detail. All posttransplant complications were graded by the Clavien score (11) and quantified by the comprehensive complication index (CCI). (12) An overall number of 315 patients were included in this analysis, 222 transplanted from livers younger or equaling 60 years of age and 93 above 60 years.
Second, we performed a multivariate logistic regression analysis and applied different, well-known, continuous risk factors (donor age, donor body mass index [BMI] , functional donor warm ischemia time (fDWIT), cold storage (CS), recipient age, and recipient Model of End-Stage Liver Disease [MELD] ) for best stratification of worse outcome in our cohort. The impact of other parameters, eg, cardiovascular risk factors and diabetes mellitus (DM) in the donor or hepatitis C infection and hepatocellular carcinoma (HCC) in the recipient, were also evaluated through logistic regression analysis (dichotomous parameters). Donor liver biopsies at the time of transplantation were available in 233 patients (74% of all DCD transplants), and the impact of graft macrosteatosis and microsteatosis on outcome was assessed. Moreover, we have correlated the donor BMI and the amount of graft steatosis.
Finally, we applied the identified risk factors in the 2 cohorts of different donor ages to define cases with increased risk for inferior survival and IC.
Retransplantations, pediatric liver transplantations, segmental grafts (living donors, split livers), domino and combined liver transplants, and machine perfused liver grafts were excluded from this analysis.
PROCESS OF DCD LIVER DONATION, PRESERVATION, AND TRANSPLANTATION
In the United Kingdom, DCD multiorgan retrievals follow the national guidelines of Maastricht III donors, (13) where a controlled withdrawal of treatment is performed on the ICU in the donor hospital. The fDWIT time is defined as duration from systolic blood pressure below 50 mm Hg to cold aortic perfusion in the DCD donor during retrieval. Such fDWIT serves as a critical measure to accept or decline a DCD liver graft if any longer than 30 minutes. Following cardiac arrest and a 5-minute "stand-off" period to certify death, a super-rapid laparotomy and aortic cannulation and high pressure cold organ flush (200 mm Hg) through the aorta is performed. (14) Following sternotomy, the thoracic aorta is clamped in the donor's chest. In addition, the portal vein or inferior mesenteric vein is cannulated to perfuse the portal system of the liver prior to hepatectomy. Low-viscosity Marshall's solution is used, apart from combined liver and pancreas retrievals, where University of Wisconsin (UW) solution was implemented for cold in situ flush. Although no heparin (or other agents) is administered systemically to the donor, 20,000 units are mixed into the first 2 bags of preservation solution. An additional liver flush through both systems (arterial and portal) with UW is performed prior to packing and transport of the organ. The common bile duct is also infused with several injections of cold preservation solution prior to hepatectomy and on the bench. The gallbladder is routinely opened, and bile fluid is flushed out.
The decision to choose a recipient for a DCD graft is made from an in-house low-risk cohort based on the general center-related allocation system in the United Kingdom. (4) For instance, potential recipients with low MELD scores are selected for DCD grafts based on an expected higher tolerance to the reperfusion insult. At pretransplant assessment (prior to listing), liver transplant candidates are evaluated regarding the potential graft to receive. Candidates waiting for retransplantation or with severe sarcopenia, increased MELD or United Kingdom Model of End-Stage Liver Disease (UKELD) scores, and higher-grade portal vein thrombosis (>grade 1) are generally not evaluated to receive a DCD liver graft. Liver transplantation at our center is performed using the classic or modified piggy-back technique, and graft reperfusion was performed through the portal vein first. We do not routinely use a renal-sparing antirejection protocol in this patient population. Our standard immunosuppression regimen introduced after DCD liver transplantation involves steroids, tacrolimus, and azathioprine or combinations with mycophenolate mofetil. 
STATISTICAL ANALYSIS
Data are presented by using the median and interquartile range (IQR) for continuous variables. The nonparametric Mann-Whitney U test was used to determine whether significant differences existed between groups. Differences in nominal data were compared by Fisher's exact test. A P value of < 0.05 was deemed statistically significant. A clinical outcomes analysis was performed through Kaplan-Meier survivor plots, and significant differences between groups were assessed by log-rank/Mantel-Cox testing. Additionally, logistic regression models were fit in order to assess the impact of individual covariates on the rate of respective events (included as continuous and/or dichotomous parameters; odds ratio [OR] ). All data were analyzed using SPSS, version 24.0 (IBM, Armonk, NY) and Prism, version 5 (Graphpad Software, San Diego, CA).
ETHICAL APPROVAL AND QUALITY CONTROL
Completeness, plausibility, and validity of the data were independently verified (by A.S., I.S., M.K., and P.M.), including objective review of all historical medical charts. The local regulatory board approval was obtained prior to study initiation and database/chart review (CARMS-02246).
Results
TRANSPLANTATION ACTIVITY USING DCD GRAFTS BETWEEN 2005 AND 2015
Almost 90% (89.2%) of our DCD liver grafts were classified as "extended," according to the British Transplant Society (BTS) guidelines, that define marginality due to the following donor factors: age > 50 years, body weight > 100 kg, duration of stay in the ICU > 5 days, fDWIT > 20 minutes, cold ischemia time (CIT) > 8 hours, and >15% graft steatosis (Fig. 1) . (5) During the past 10 years, we documented a constantly increasing number of such defined extended DCD transplants at our center ( Fig. 1 ). Importantly though, although the majority of donor parameters, eg, ICU stay, BMI, and fDWIT remained unchanged ( Fig. 2B-D 
COMPARISON OF DCD TRANSPLANTS USING GRAFTS BELOW OR ABOVE 60 YEARS
In a second step, we therefore analyzed our DCD population in terms of donor age 60 and >60 years. Most general parameters were comparable between the groups, defined by donor age (Table 1) . For example, donor BMI (24.7 versus 25.2 kg/m 2 , fDWIT (17 versus 18 minutes), CIT (6.9 versus 7.1 hours), recipient age (56 versus 57 years), recipient MELD (13.1 versus 12.6 points), and balance of risk (BAR) score (4 versus 5 points) were similar between younger and older DCD donors (Table 1 ). In relation with the higher median donor age in the older DCD group (67 versus 45 years; P < 0.001), the following significant differences were observed: cause of donor death (trauma, 18.5% versus 4.3%, P < 0.001; cerebrovascular accident, 45.0% versus 66.3%, P < 0.001) and donor risk index (DRI; 2.4 versus 3.4 points; P < 0.001; Table 1 Accordingly, the majority of elderly donors had a past medical history of cardiovascular disease (56% versus 26%; P < 0.001). Despite that, we failed to observe any impact on outcome in DCD liver transplantation from elderly donors with or without cardiovascular disease (Table 1) .
ADVANCED DONOR AGE ALONE DID NOT INCREASE POSTTRANSPLANT MORBIDITY AND MORTALITY
In a third step, we investigated the impact of donor age on outcome. For this purpose, we assessed all perioperative and postoperative complications after orthotopic liver transplantation (OLT) in 2 patient cohorts, differing in donor age (60 versus > 60 years). Older DCD grafts underwent transplantation within similar time (5.3 versus 5.2 hours) and comparable transfusion requirements (red blood cells, 2 versus 2; fresh frozen plasma, 6 versus 4.5; platelets, 2 versus 1; Supporting Table 1 ; Supporting Fig. 1A ). Peak liver transaminases during the first week after OLT were not different (Supporting Table 2 ; Supporting Fig.  1C ), and DCD livers demonstrated immediate graft function in both groups (Table 2; Supporting Tables 1  and 2 ; Supporting Fig. 1B ). In addition, vascular and biliary complications did not occur more frequently in transplants from elderly DCD donors (Table 2) , especially intrahepatic cholangiopathy (IC), which was detected in 11% of DCD liver recipients (11.3% versus 11.8%; Table 2 ; Supporting Fig. 1E ). Overall, we found a low rate of graft loss due to severe IC of 3.2% (2.3% versus 5.4%; P 5 0.13). More than half of all DCD recipients (59% versus 48%) presented with acute kidney injury postoperatively with the need for renal replacement therapy in 23% of the entire cohort (40.5% versus 42.4%; Supporting Fig. 1F ), but importantly the kidney function recovered (Supporting Fig.  1G ; Supporting Table 2 ). The final classification of highest overall complications occurred equally in DCD liver transplantation from older compared with younger donors (Clavien score; Table 2 ). The median cumulative CCI after OLT was 42.7 points in both groups, corresponding to the similar distribution of all other types of complications as well as the same length of ICU and hospital stay ( Table 2 ; Supporting Fig. 1D ). Such results were paralleled by an equally low 3-month mortality rate (7.2% versus 6.5%; Table 2 ), regardless of the higher donor age and DRI and a similar 5-year graft and patient survival (Table 1 ; Fig. 3A,B) .
GRAFT LOSS AND IC AFTER DCD LIVER TRANSPLANTATION ARE PREDICTABLE BY AN INCREASED DONOR BMI
In a last step, we searched for key factors of graft loss by multivariate analysis. Most well-known risk factors (donor age, CIT, fDWIT, recipient age, recipient MELD) failed to predict graft survival in our cohort (Table 3) . Instead, graft loss was significantly stratified by an increasing donor BMI (continuous and dichotomous variable; Table 3 ). Notably, 5-year patient and graft survival in the aged cohort was excellent (88% and 80%), when respecting donor BMI thresholds (Fig.  3C,D) . In addition, donor BMI stratified significantly also the younger DCD donor population in contrast to all other risk factors (Fig. 3C,D) . The ratio of graft loss in patients exceeding thresholds (positive predictive value) was highest in donor BMI >25 kg/m 2 (29% and 32.1%), while lower positive predictive values were found for all other risk factors including donor age (Supporting Table 3 ). To further characterize DCD livers from donors with a higher BMI, we were interested in the degree of steatosis in our DCD grafts. However, histology reports were only available in 233 DCD grafts of our cohort (74%). Notably, significantly more DCD livers showed features of macrosteatosis, when the donor BMI was higher than 25 kg/m 2 compared with the group with a lower donor BMI of 25 kg/m 2 (28% versus 54.6%; P < 0.001; Table 4 ). Importantly, the vast majority of such livers showed either no steatosis or only a mild degree of macrosteatosis (30%), and graft steatosis was therefore not found to impact on graft loss, explored through our multivariate analysis (Table  3) . No differences were found in terms of graft microsteatosis (Table 3) . Donor DM and cardiovascular diseases were not found to impact on graft loss in our DCD cohort (Table 3) .
Correspondingly, most recipients who developed IC underwent transplantation from a donor with a BMI > 25 kg/m 2 ( Fig. 4A,B) . This became particularly evident in the older DCD donor group, above an age of 60 years (Fig. 4B) . All other well-known risk factors showed the expected tendency, but they did not reach significance because of the homogeneous expression of variables within our DCD population (Table 3; Supporting  Table 3 ). The median duration of donor hepatectomy showed a tendency toward a longer duration in donors with higher BMI but did not reach statistical significance (43 versus 48 minutes; not significant).
Discussion
We show in this analysis of a large single-center DCD liver transplant population, that a donor age above 60 years is not a risk factor per se for DCD liver transplants.
This conclusion is based on similar outcome for vascular, biliary, and overall complications in donors above 60 years of age. Second, we found unexpectedly, that donor BMI was more predictive for graft loss in our DCD population than previously identified risk factors, eg, recipient MELD, donor WIT, and CIT. We believe that these results are important because in the United Kingdom and also in other European countries, due to an aging donor population, many liver grafts from older donors, including DCD, are offered.
Clear definitions for advanced donor age in DCD livers are still lacking. In the United States, some transplant centers suggest donor age thresholds already above 45 years, particularly in the context of longer graft warm ischemia time (WIT) and CIT. (6) Centers in other countries such as the Netherlands follow strict national guidelines to avoid transplantation of DCD livers, above a donor age of 60 years. (15) However, in our center the percentage of DCD liver grafts older than 60 years accumulated to almost 70% in 2016. We confirm in our analysis that this policy to use DCD grafts at a higher donor age does not necessarily provoke inferior outcome. Our results may serve as an important guideline for other centers and countries, where DCD livers from elderly donors are frequently declined, despite otherwise low accumulating risk.
The second finding of our analysis is a significant negative impact of higher donor BMI on DCD transplant outcome. Despite the same overall rate of IC in both cohorts (above and below 60 years of donor age), the majority of elderly grafts, which developed IC, . Today, where such donors are frequently allocated, a suggested donor BMI cutoff at 25 kg/m 2 may appear rather low, potentially discriminating many livers. This cutoff, however, presented the median of our DCD population and correlated significantly with histologically proven macrosteatosis, known to cause more reperfusion injury, graft dysfunction, and biliary injury. (16) In addition to an impaired liver function, when large fat droplets have accumulated, (17) organ procurement from donors with a higher BMI may transmit further risk for higher reperfusion injury due to prolonged donor surgery and less optimal flushing in such situations. We would, however, not suggest declining DCD livers solely based on a high BMI but rather be aware of the potential risk. Using DCD livers from donors with a BMI of more than 25 kg/m 2 is successful, if the sum of all risk factors is low (donor age, donor diabetes, donor hypertension, donor WIT, CIT, and recipient risk factors). (17) Despite the impact of increased donor BMI, the overall outcome of DCD liver transplantation seems very good, which mainly relates to careful donor and recipient selection, to minimize further risk factors. At our center, DCD liver grafts with a prolonged fDWIT of more than 30 minutes are mostly declined. In addition, we aim, as any other centers experienced in DCD transplantation, to thoroughly organize retrieval, transport, and recipient management prior to transplantation, to minimize duration of CIT to a maximum of 6 to 8 hours. Selection of the appropriate recipient starts already at the time of pretransplant assessment of a potential candidate. At our center, we precisely define which candidate is "fit" enough for DCD grafts. Altogether, such efforts led to an overall low rate of graft loss due to PNF and IC.
Additional, ex vivo graft treatment, such as normothermic or hypothermic machine perfusion, may allow further advances in the field. (18) (19) (20) And such boundaries may become extended in the near future, when the impact of machine perfusion preservation on extended DCD liver grafts is better defined.
Our study has several shortcomings. First, though our center has a large amount of experience in DCD transplantation, the results need to be validated in national DCD cohorts, which we have recently initiated. Second, we failed to confirm that the length of donor WIT or graft CIT alone is superior to donor BMI, as is suggested by many. (2, 7, 21) The reason behind this may be related to relatively short fDWIT in our accepted grafts. High donor age may be in fact more relevant in a DCD population with significantly longer CITs and WITs.
Third, the threshold of 60 years is somewhat arbitrarily chosen, and it may be at different levels for different populations. For example, some authors reported that patients transplanted with a DCD donor liver of more than >45 to > 60 years are at higher risk for inferior outcome. (2, 9) These results, however, present relatively small cohorts, particularly in the older donor age group. Moreover, cohorts from the United States show differences in most other donor risk factors, and donors in general are much younger compared with European countries. (6) Recently, Goldberg et al. reported outcomes of more than 700 DCD liver transplantations in the United States. (8) Compared with our single-center cohort, the DCD population from elderly donors of >60 years is rather small with 4.4% (n 5 33/744). Moreover, at our center, we have noticed a significant increasing median donor age, peaking at 68 years in 2015. In this context, we believe that our results are of importance, particularly for centers, where the donor age cutoff "60 years" appears as 1 guideline to decline DCD grafts, regardless of other risk factors.
In addition, we postulate that donor age can be more advanced when other donor and recipient risk factors are limited, as it is common practice in a center allocation system. Therefore, donor age alone appeared potentially less important for stratifying survival and morbidity in our center. These results may be different, however, in MELD-based allocation systems. In addition, at our center, further DCD donor risk factors are limited by careful selection. For example, high donor gamma-glutamyltransferase and DM in the donor are generally avoided as potential predictors of further potential risk of liver steatosis or inflammation in the donor. Accumulation of too many risk factors may lead to an inferior outcome following DCD grafting. Further analysis of large DCD cohorts may help to decide which risk factor combination requires further graft treatment by machine perfusion or when simply to say no to a certain donor and recipient combination.
In summary, DCD donor BMI appears as an additional important risk factor for inferior outcome in the setting of DCD liver transplantation. Respecting donor BMI threshold may help when deciding whether to accept high-risk grafts particularly from elderly DCD donors.
